Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and FOLFOX in Locally Advanced Esophageal Cancer
NCT01212822Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Apr 2011
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in esophageal cancer, gastric cancer (GC), sponsored by Fox Chase Cancer Center. Started Apr 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT01212822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01212822.